JP2008500815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500815A5 JP2008500815A5 JP2007504185A JP2007504185A JP2008500815A5 JP 2008500815 A5 JP2008500815 A5 JP 2008500815A5 JP 2007504185 A JP2007504185 A JP 2007504185A JP 2007504185 A JP2007504185 A JP 2007504185A JP 2008500815 A5 JP2008500815 A5 JP 2008500815A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pharmaceutical composition
- tumor
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 229940034982 antineoplastic agent Drugs 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940122558 EGFR antagonist Drugs 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 1
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55455504P | 2004-03-19 | 2004-03-19 | |
| US60/554,555 | 2004-03-19 | ||
| US62426404P | 2004-11-02 | 2004-11-02 | |
| US60/624,264 | 2004-11-02 | ||
| PCT/US2005/009583 WO2005090407A1 (en) | 2004-03-19 | 2005-03-21 | Human anti-epidermal growth factor receptor antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500815A JP2008500815A (ja) | 2008-01-17 |
| JP2008500815A5 true JP2008500815A5 (enExample) | 2010-05-27 |
| JP4734319B2 JP4734319B2 (ja) | 2011-07-27 |
Family
ID=34964896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504185A Expired - Lifetime JP4734319B2 (ja) | 2004-03-19 | 2005-03-21 | ヒト抗上皮成長因子受容体抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7598350B2 (enExample) |
| EP (2) | EP2332990A1 (enExample) |
| JP (1) | JP4734319B2 (enExample) |
| CN (1) | CN103007279B (enExample) |
| AU (1) | AU2005224267B2 (enExample) |
| CA (1) | CA2560305C (enExample) |
| CY (2) | CY1113037T1 (enExample) |
| DK (1) | DK1735348T3 (enExample) |
| ES (1) | ES2387809T3 (enExample) |
| HU (1) | HUS000495I2 (enExample) |
| LT (1) | LTC1735348I2 (enExample) |
| LU (1) | LU93093I2 (enExample) |
| MX (1) | MXPA06010715A (enExample) |
| NL (1) | NL300819I2 (enExample) |
| PL (1) | PL1735348T3 (enExample) |
| PT (1) | PT1735348E (enExample) |
| RU (1) | RU2402569C2 (enExample) |
| WO (1) | WO2005090407A1 (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| EE200100603A (et) * | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega |
| AU2001295002B2 (en) * | 2000-08-09 | 2007-05-31 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| AU2007212447B2 (en) | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| CN101058609B (zh) * | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
| JP2009540015A (ja) * | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗ｅｇｆｒ抗体の凍結乾燥製剤 |
| WO2008033495A2 (en) * | 2006-09-15 | 2008-03-20 | Life Science Pharmaceuticals | Method for detecting and treating skin disorders |
| US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| EA021967B1 (ru) * | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| CA2714939A1 (en) * | 2008-02-20 | 2009-08-27 | Joyce A. Schroeder | Use of therapeutic peptides for the treatment and prevention of cancer |
| MX337991B (es) | 2008-08-05 | 2016-03-30 | Toray Industries | Metodo para detectar cancer. |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| KR101108642B1 (ko) * | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| CN101875695B (zh) * | 2009-11-11 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其编码基因与应用 |
| CN101704891B (zh) | 2009-11-11 | 2011-11-09 | 中国人民解放军军事医学科学院生物工程研究所 | 一种针对表皮生长因子受体的抗体及其编码基因与应用 |
| CN101875696B (zh) | 2009-11-11 | 2012-02-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其制备方法与应用 |
| JP5843783B2 (ja) * | 2009-12-18 | 2016-01-13 | サノフイ | ＧＰＶＩに対する新規アンタゴニスト抗体および該抗体のＦａｂフラグメントならびにこれらの使用 |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| KR101871704B1 (ko) | 2010-02-04 | 2018-06-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| KR20130096731A (ko) | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법 |
| KR101273918B1 (ko) | 2010-09-17 | 2013-06-13 | 강원대학교산학협력단 | 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 |
| US9585938B2 (en) | 2010-10-12 | 2017-03-07 | Arizona Cancer Therapeutics, Llc | EGFR-based peptides |
| US10066004B2 (en) | 2010-10-12 | 2018-09-04 | Arizona Cancer Therapeutics, Llc | EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3 |
| CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| SG194567A1 (en) | 2011-04-21 | 2013-12-30 | Seattle Genetics Inc | Novel binder-drug conjugates (adcs) and their use |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| ES2629061T3 (es) | 2011-08-04 | 2017-08-07 | Toray Industries, Inc. | Método para la detección de cáncer pancreático |
| KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
| ES2672695T3 (es) | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| JP2014533954A (ja) | 2011-11-21 | 2014-12-18 | イミュノジェン， インコーポレイテッド | Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法 |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
| IN2014KN01714A (enExample) | 2012-02-21 | 2015-10-23 | Toray Industries | |
| AU2013223143B2 (en) | 2012-02-21 | 2017-12-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CA2866612C (en) | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| PT2832365T (pt) | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
| JP6441792B2 (ja) * | 2012-05-17 | 2018-12-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｅｇｆｒに結合する抗原結合蛋白質 |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| CA2879185C (en) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Method for detecting cancer |
| WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| US9862932B2 (en) | 2012-07-24 | 2018-01-09 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| US9921222B2 (en) | 2012-07-31 | 2018-03-20 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug |
| EP2890720B1 (en) * | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| BR112015025549A2 (pt) | 2013-04-07 | 2017-10-10 | Bioex Therapeutics Inc | anticorpo contra o receptor do fator de crescimento epidérmico |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2015038984A2 (en) | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| AU2014368453B2 (en) * | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| AU2014372833B2 (en) | 2013-12-23 | 2019-08-22 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
| CN111499753B (zh) | 2014-03-03 | 2022-10-21 | 高雄医学大学 | 双功能抗体及其用途 |
| EP3172231B1 (en) * | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| CN105315371B (zh) | 2015-03-05 | 2018-05-29 | 北京百特美博生物科技有限公司 | 抗人il-17单克隆抗体 |
| TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
| SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| MX2017017138A (es) | 2015-06-23 | 2018-04-30 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp. |
| TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Ｈｅｒ３抗體 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US20190233523A1 (en) | 2016-09-26 | 2019-08-01 | Imclone Llc | Combination therapy for cancer |
| AU2017380871C1 (en) | 2016-12-21 | 2025-05-15 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CN113603783B (zh) * | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
| JP2022515256A (ja) * | 2018-12-25 | 2022-02-17 | ソル － ゲル テクノロジーズ リミテッド | Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療 |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| CN117186219B (zh) * | 2020-04-17 | 2024-07-12 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| JP2023536665A (ja) * | 2020-08-05 | 2023-08-28 | オハイオ・ステイト・イノベーション・ファウンデーション | アダプターポリペプチドおよびその使用方法 |
| EP4058474B1 (en) * | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| US20240307539A1 (en) | 2020-09-30 | 2024-09-19 | Institute Of Zoology, Chinese Academy Of Science | Egfr-targeting chimeric antigen receptor |
| US20250270304A1 (en) * | 2020-12-23 | 2025-08-28 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
| JP2025541200A (ja) | 2022-12-15 | 2025-12-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん処置のための併用療法 |
| WO2025237392A1 (zh) * | 2024-05-16 | 2025-11-20 | 徕特康(苏州)生物制药有限公司 | 新型抗egfr抗体、药物偶联物及其用途 |
| WO2025247261A1 (zh) * | 2024-05-30 | 2025-12-04 | 爱尔利希生物科技有限公司 | 抗egfr抗体药物偶联物及其用途 |
| WO2026019994A1 (en) | 2024-07-19 | 2026-01-22 | Genentech, Inc. | Methods and compositions comprising a shp2 inhibitor and an egfr inhibitor |
| WO2026150329A1 (ko) * | 2025-01-10 | 2026-07-16 | 주식회사 네옥 바이오 | 항 egfr/muc1 이중특이성 항체의 항체-약물 컨쥬게이트 {antibody-drug conjugate of anti-egfr/muc1 bispecific antibody} |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| DE2808353C2 (de) * | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Ohrring |
| US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| ATE119198T1 (de) | 1988-04-16 | 1995-03-15 | Celltech Ltd | Verfahren zur herstellung von proteinen mittels rekombinanter dna. |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000916A2 (en) * | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
| US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0525109A4 (en) | 1990-04-16 | 1993-06-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) * | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU658396B2 (en) * | 1991-03-06 | 1995-04-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric monoclonal antibodies |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5559235A (en) * | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| CA2183655C (en) * | 1994-02-23 | 2001-03-06 | Lee D. Arnold | 4-polycyclic amino-substituted quinazoline derivatives |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| HU221001B1 (hu) * | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| JP3249007B2 (ja) * | 1994-03-17 | 2002-01-21 | 富士通株式会社 | 半導体装置、その特性評価方法及び設計方法 |
| US5656655A (en) * | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
| US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
| US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
| US5604233A (en) * | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| PT706799E (pt) * | 1994-09-16 | 2002-05-31 | Merck Patent Gmbh | Imunoconjugados ii |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
| US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6140317A (en) * | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| US5925566A (en) * | 1996-06-06 | 1999-07-20 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
| US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| AU4079999A (en) * | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| CZ303899B6 (cs) | 1998-09-29 | 2013-06-19 | Wyeth Holdings Corporation | Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| EE200100603A (et) * | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega |
| EP1054018B1 (en) | 1999-05-18 | 2009-01-28 | Dyax Corp. | Fab fragment libraries and methods for their use |
| EP2110138A1 (en) * | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| AU2001295002B2 (en) | 2000-08-09 | 2007-05-31 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US6699473B2 (en) * | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| WO2002087618A1 (en) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Preventive/therapeutic method for cancer |
| KR100945108B1 (ko) * | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체 |
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| EP1519747A4 (en) * | 2002-01-28 | 2006-03-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) |
| PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| US20050176633A1 (en) * | 2002-03-08 | 2005-08-11 | Axel Ullrich | Use of egfr transactivation inhibitors in human cancer |
| US20060264353A1 (en) * | 2002-03-21 | 2006-11-23 | Maxey Kirk M | Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension |
| AU2003241898A1 (en) * | 2002-06-03 | 2003-12-19 | Mitsubishi Pharma Corporation | PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR |
| CA2491471A1 (en) * | 2002-07-03 | 2004-01-15 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof |
| JP2006505546A (ja) * | 2002-10-10 | 2006-02-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 二重特異性抗ＥｒｂＢ抗体および腫瘍治療でのその使用 |
| EP2365001A3 (en) | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| PT1687338E (pt) * | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| EP1713502A1 (de) * | 2004-02-12 | 2006-10-25 | MERCK PATENT GmbH | Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| JP5835204B2 (ja) | 2012-12-20 | 2015-12-24 | 信越化学工業株式会社 | レジスト材料及びこれを用いたパターン形成方法 |
-
2005
- 2005-03-21 ES ES05732383T patent/ES2387809T3/es not_active Expired - Lifetime
- 2005-03-21 AU AU2005224267A patent/AU2005224267B2/en not_active Ceased
- 2005-03-21 WO PCT/US2005/009583 patent/WO2005090407A1/en not_active Ceased
- 2005-03-21 CA CA2560305A patent/CA2560305C/en not_active Expired - Fee Related
- 2005-03-21 EP EP10176938A patent/EP2332990A1/en not_active Withdrawn
- 2005-03-21 EP EP05732383A patent/EP1735348B1/en not_active Expired - Lifetime
- 2005-03-21 CN CN201210509997.4A patent/CN103007279B/zh not_active Expired - Fee Related
- 2005-03-21 PL PL05732383T patent/PL1735348T3/pl unknown
- 2005-03-21 MX MXPA06010715A patent/MXPA06010715A/es active IP Right Grant
- 2005-03-21 US US10/593,804 patent/US7598350B2/en active Active
- 2005-03-21 JP JP2007504185A patent/JP4734319B2/ja not_active Expired - Lifetime
- 2005-03-21 RU RU2006137060/13A patent/RU2402569C2/ru not_active IP Right Cessation
- 2005-03-21 DK DK05732383.4T patent/DK1735348T3/da active
- 2005-03-21 PT PT05732383T patent/PT1735348E/pt unknown
-
2012
- 2012-08-06 CY CY20121100704T patent/CY1113037T1/el unknown
-
2016
- 2016-05-20 CY CY2016016C patent/CY2016016I1/el unknown
- 2016-05-31 LU LU93093C patent/LU93093I2/fr unknown
- 2016-06-01 LT LTPA2016020C patent/LTC1735348I2/lt unknown
- 2016-06-14 HU HUS1600030C patent/HUS000495I2/hu unknown
- 2016-06-14 NL NL300819C patent/NL300819I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006137060A (ru) | Человеческие антитела к рецептору эпидермального фактора роста | |
| JP2013529183A5 (enExample) | ||
| JP2013522237A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2023070678A5 (enExample) | ||
| JP2009525764A5 (enExample) | ||
| JP2023539715A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| JP2015512877A5 (enExample) | ||
| HRP20131107T1 (hr) | Anti-notch1 nrr-protutijela i postupak njihove uporabe | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2014530215A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2014509593A5 (enExample) | ||
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| RU2018114904A (ru) | Антитело против garp | |
| JP2015529641A5 (enExample) | ||
| JP2016166203A5 (enExample) | ||
| JP2015212281A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
| JP2012501648A5 (enExample) |